Amniotics AB

Equities

AMNI

SE0015961016

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:25:49 2024-04-26 am EDT			5-day change	1st Jan Change
0.0038 ^SEK	0.00%		0.00%	-57.78%

Mar. 22	Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.	CI
Feb. 22	Amniotics AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Amniotics AB Reports Earnings Results for the Full Year Ended December 31, 2023

February 22, 2024 at 09:05 am EST

Amniotics AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was SEK 6.5 million compared to SEK 0.553 million a year ago. Net loss was SEK 30.87 million compared to SEK 48.05 million a year ago.

Basic loss per share from continuing operations was SEK 0.07 compared to SEK 2.99 a year ago.

Latest news about Amniotics AB

Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.	Mar. 21	CI
Amniotics AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Amniotics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Amniotics Secures Orphan Designation for Lung Injury Therapy from European Commission	Dec. 14	MT
Amniotics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 27	CI
Amniotics AB Gets Renewed GMP Certification for Medicinal Products Manufacturing Site	Nov. 23	MT
European Medicines Agency Panel Backs Amniotics AB’s PulmoStem for Orphan Designation	Nov. 20	MT
Amniotics AB Receives Positive Opinion on Orphan Designation for PulmoStem from the European Medicines Agency for the Treatment of Primary Graft Dysfunction Following Lung Transplantation	Nov. 20	CI
Amniotics AB Receives Final Clinical Study Report for the Phase Ib Clinical Trial	23-09-13	CI
Certain Ordinary Shares of Amniotics AB are subject to a Lock-Up Agreement Ending on 9-SEP-2023.	23-09-08	CI
Amniotics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
Amniotics AB Announces Delay in Publication of Earnings Result for the Second Quarter of 2023	23-08-17	CI
Amniotics AB Announces Positive Interim Results with CogniStem	23-06-04	CI
Amniotics AB Receives Positive Topline Results from Clinical Phase Ib Study with PulmoStem	23-05-25	CI
Amniotics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Amniotics AB Auditor Raises 'Going Concern' Doubt	23-04-27	CI
Swedish Biotech Amniotics Namese New CFO	23-04-20	MT
Amniotics Announces CFO Changes	23-04-19	CI
Amniotics AB Receives Positive Information About Safety Data for PulmoStem in Clinical Study	23-03-02	CI
Amniotics AB Completes Phase Ib Study of PulmoStem	23-02-16	CI
Amniotics AB Reports Earnings Results for the Full Year Ended December 30, 2022	23-01-19	CI
Amniotics AB Reports Earnings Results for the Fourth Quarter Ended December 30, 2022	23-01-19	CI
Amniotics AB Receives Positive Safety Data from PulmoStem™ Clinical Study	22-12-19	CI
Amniotics-led Consortium Wins EU Grant for Anti-Cancer Cells Program	22-11-14	MT
Amniotics AB Invites by European Innovation Council to Finalise Grant Agreement with the as Part of Consortium Set to Receive Grant of EUR 3.8 Million from the EIC Pathfinder Programme	22-11-14	CI

Chart Amniotics AB

Duration

Period

More charts

Company Profile

Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AMNIOTICS AB	-57.78%	947K
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research